BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30054137)

  • 1. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study.
    Semenkovich TR; Subramanian M; Yan Y; Hofstetter WL; Correa AM; Cassivi SD; Inra ML; Stiles BM; Altorki NK; Chang AC; Brescia AA; Darling GE; Allison F; Broderick SR; Etchill EW; Fernandez FG; Chihara RK; Litle VR; Muñoz-Largacha JA; Kozower BD; Puri V; Meyers BF
    Ann Thorac Surg; 2019 Sep; 108(3):828-836. PubMed ID: 31229485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer.
    Brescia AA; Broderick SR; Crabtree TD; Puri V; Musick JF; Bell JM; Kreisel D; Krupnick AS; Patterson GA; Meyers BF
    Ann Thorac Surg; 2016 Jan; 101(1):200-8; discussion 208-10. PubMed ID: 26507424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy.
    Samson P; Puri V; Broderick S; Patterson GA; Meyers B; Crabtree T
    Ann Thorac Surg; 2017 Feb; 103(2):406-415. PubMed ID: 28024648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
    Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.
    Samson P; Puri V; Robinson C; Lockhart C; Carpenter D; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    Ann Thorac Surg; 2016 Jun; 101(6):2102-11. PubMed ID: 27083246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.
    Giugliano DN; Berger AC; Pucci MJ; Rosato EL; Evans NR; Meidl H; Lamb C; Levine D; Palazzo F
    J Gastrointest Surg; 2017 Sep; 21(9):1377-1384. PubMed ID: 28664255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation.
    Spector R; Zheng Y; Yeap BY; Wee JO; Lebenthal A; Swanson SJ; Marchosky DE; Enzinger PC; Mamon HJ; Lerut A; Odze R; Srivastava A; Agoston AT; Tippayawang M; Bueno R;
    Semin Thorac Cardiovasc Surg; 2015; 27(2):205-15. PubMed ID: 26686448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
    Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
    Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.